Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Group A: Saline Group Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

NCT06178991
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
8,795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
106
States / cities
Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy

NCT02597660
View directory record Official record
Conditions
Tendinopathy
Interventions
Somatropin, Bacteriostatic saline, Progressive exercise program, Patellar tendon biopsy
Drug · Other · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 15, 2026, 10:29 PM EDT
Terminated Not applicable Interventional Results available

Cycling of Sedative Infusions in Critically Ill Pediatric Patients

NCT01333059
View directory record Official record
Conditions
Respiratory Failure
Interventions
Midazolam, Normal saline, Fentanyl
Drug
Lead sponsor
Javier Gelvez, MD
Other
Eligibility
Up to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Preprandial Ghrelin Effect

NCT02913703
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Ghrelin, Saline
Drug · Other
Lead sponsor
Jenny Tong, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 15, 2026, 10:29 PM EDT
Recruiting Phase 2 Interventional

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

NCT07103746
View directory record Official record
Conditions
Autoimmune Disorders
Interventions
Ublituximab, Placebo for Ublituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2 Interventional

AZD6765 Severe Major Depressive Disorder (MDD) IV

NCT00781742
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%

NCT01690663
View directory record Official record
Conditions
Post Surgical Pain
Interventions
Bupivacaine 0.25%, Dexamethasone, normal saline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 15, 2026, 10:29 PM EDT
Terminated Phase 2 Interventional Results available

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

NCT01467076
View directory record Official record
Conditions
Prematurity, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn
Interventions
Aerosolized Normal Saline, Inhaled PGE1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 15, 2026, 10:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

NCT01164514
View directory record Official record
Conditions
Bacterial Sepsis
Interventions
CPG 7909, J5-OMP Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

NCT00912925
View directory record Official record
Conditions
Mucopolysaccharidosis I, Hurlers Syndrome, Hurler-Scheie Syndrome
Interventions
rhIDU (recombinant human-Alpha-L-Iduronidase), Placebo
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
5 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy

NCT00004547
View directory record Official record
Conditions
Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
Interventions
Surgery, Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin, Postoperative dwell with paclitaxel and 5-FU
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501

NCT01509638
View directory record Official record
Conditions
Retraction of Colostomy
Interventions
Group 1 Standard of Care, Group 2 EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Weston, Florida • Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 15, 2026, 10:29 PM EDT
Enrolling by invitation Phase 4 Interventional

Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery

NCT06995352
View directory record Official record
Conditions
Moderate-to-severely Painful Ankle Surgery
Interventions
Popliteal nerve block including liposomal bupivacaine, Adductor canal nerve block including liposomal bupivacaine, Continuous popliteal nerve block with normal saline, Popliteal nerve block with exclusively unencapsulated bupivacaine, Adductor canal nerve block with exclusively unencapsulated bupivacaine, Continuous popliteal nerve block with unencapsulated bupivacaine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Results available

Preoperative IV Versus Oral Acetaminophen

NCT03468920
View directory record Official record
Conditions
Pain, Postoperative
Interventions
IV Acetaminophen, PO Acetaminophen, PO Placebo, IV Solution Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

2 Dose Neuraxial Morphine for Prevention of PDPH

NCT02473276
View directory record Official record
Conditions
Postdural Puncture Headache
Interventions
Morphine, Sterile normal saline
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
4
States / cities
Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of CJCV2 With and Without ALFQ

NCT05500417
View directory record Official record
Conditions
Campylobacter Infection
Interventions
ALFQ, CJCV2
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Not listed Phase 2 Interventional

Efficacy of CTM for Tennis ELbow

NCT06171555
View directory record Official record
Conditions
Tennis Elbow, Lateral Epicondylitis \(Tennis Elbow\), Lateral Elbow Tendinopathy
Interventions
CTM, Celestone
Device · Drug
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Effects of Changes in Fluid Status on Right Ventricular Volumes and Function

NCT02967315
View directory record Official record
Conditions
Tetralogy of Fallot
Interventions
Cardiac Magnetic Resonance Imaging (CMRI), Central venous line placement, Chest X-ray, Fluid administration, Blood Draw, Pregnancy test, Electrocardiogram
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

NCT01683071
View directory record Official record
Conditions
Postoperative Pain
Interventions
Placebo, EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2 Interventional

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

NCT04975893
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, mRNA-1647
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Peoria, Illinois • Lenexa, Kansas • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Recruiting Phase 4 Interventional

Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty

NCT07775248
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grosse Pointe Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy

NCT01802411
View directory record Official record
Conditions
Posterolateral Thoracotomy, Postoperative Pain
Interventions
EXPAREL 266 mg, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Miami, Florida • Shreveport, Louisiana • Fargo, North Dakota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 15, 2026, 10:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 15, 2026, 10:29 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

NCT06899802
View directory record Official record
Conditions
Encephalitis
Interventions
MVA-BN-WEV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Sacramento, California • Lilburn, Georgia • Lenexa, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 15, 2026, 10:29 PM EDT